Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome (Q44589429)
Jump to navigation
Jump to search
scientific article published on 3 October 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome |
scientific article published on 3 October 2006 |
Statements
1 reference
Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome (English)
1 reference
Irit Avivi
1 reference
Eldad J Dann
1 reference
Rachel Bar-Shalom
1 reference
Ada Tamir
1 reference
Nissim Haim
1 reference
Menachem Ben-Shachar
1 reference
Tzila Zuckerman
1 reference
Mark Kirschbaum
1 reference
Odelia Goor
1 reference
Diana Libster
1 reference
Jacob M Rowe
1 reference
Ron Epelbaum
1 reference
3 October 2006
1 reference
Identifiers
1 reference